DC-806
Sponsors
DICE Therapeutics Inc., DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Conditions
Healthy ParticipantsHealthy VolunteersPlaque Psoriasis
Phase 1
A Drug-Drug Interaction Study to Assess the Pharmacokinetics of DC-806 When Orally Administered Alone, When Coadministered With Itraconazole, and When Coadministered With Carbamazepine in Healthy Adult Participants
CompletedNCT05994807
Start: 2023-08-08End: 2023-09-20Updated: 2023-10-04
Mass Balance and Pharmacokinetics (PK) of [14C]-DC-806 in Healthy Male Participants
CompletedNCT06045000
Start: 2023-09-14End: 2023-10-02Updated: 2025-05-04
A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy Participants
CompletedNCT06092931
Start: 2023-10-16End: 2023-11-28Updated: 2024-01-11
A Study to Assess S011806 (DC-806 or LY4100504) in Healthy Adult Participants and Participants With Chronic Plaque Psoriasis
CompletedNCT06808815
Start: 2021-09-22End: 2022-08-23Updated: 2025-02-05
Phase 2
A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis
CompletedNCT05896527
Start: 2023-05-02End: 2024-03-25Updated: 2025-04-04
A Multicenter, Randomized, Double-blind, Placebo- controlled, Parallel-group, Dose-ranging Study to Evaluate the Efficacy and Safety of DC-806 in Participants with Moderate to Severe Plaque Psoriasis
CompletedCTIS2022-502249-90-00
Start: 2023-08-31End: 2024-03-25Target: 206Updated: 2024-04-22